CytomX Therapeutics Profile

29.22
USD 0.62  2.17%
100%
96%

CytomX Therapeutics exotic insider transaction detected

CytomX Therapeutics Inc insider trading alert for general transaction of common stock by Sean McCarthy, President and CEO, on February 12, 2018. This event was filed by Cytomx Therapeutics Inc with SEC on 2018-02-12. Annual statement of changes in beneficial ownership - SEC Form 5 [view details]   

CytomX Therapeutics Summary

CytomX Therapeutics Inc (CTMX) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 78 people. CytomX Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 1.1 B. CytomX Therapeutics Inc has 38.41 M outstanding shares of which 1.1 M shares are currently shorted by private and institutional investors with about 3.65 trading days to cover. CytomX Therapeutics currently holds about 331.28 M in cash with 150.31 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.62.
Check CytomX Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected CytomX Therapeutics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

CytomX Therapeutics Against Markets

Risk Adjusted
Performance Score (0 to 100)
18 
Chance of
Financial Distress (0 to 100%)
< 36% 
Equity ratings for CytomX Therapeutics Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. CytomX Therapeutics is traded on NASDAQ in USA. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameCytomX Therapeutics Inc
President CEO, DirectorSean McCarthyAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationCALIFORNIA, U.S.A
Business Address151 Oyster Point Boulevard
ExchangeNASDAQ
CIK Number01501989.0
CUSIP23284F105
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.cytomx.com
Contact Number650 515 3185
CurrencyUSD - US Dollar

Current Sentiment - CTMX

CytomX Therapeutics Inc Investor Sentiment
Most of Macroaxis users are currently bullish on CytomX Therapeutics Inc. What is your opinion about investing in CytomX Therapeutics Inc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip  Hide

Recommendations

CytomX Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
19.5Buy2Odds
CytomX Therapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
CytomX Therapeutics Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

CytomX Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.45March 6, 2017
CytomX Therapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

CytomX Therapeutics Corporate Directors
Matthew Young Independent Director, MBA
Marion McCourt Director
Charles Fuchs Director